<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335895">
  <stage>Registered</stage>
  <submitdate>26/08/2010</submitdate>
  <approvaldate>31/08/2010</approvaldate>
  <actrnumber>ACTRN12610000726055</actrnumber>
  <trial_identification>
    <studytitle>Comparing accelerated vs. classic vaccination protocols regarding the efficacy of hepatitis B vaccination in prisoners</studytitle>
    <scientifictitle>Comparison of efficacy of vaccination against hepatitis B infection (anti-hepatitis B surface-antigen (HBS) antibody titers) among prisoners in Iran after administering either accelerated or classic vaccination schedules</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>immunity against hepatitis B virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Other public health</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>intramuscular administration of 20 mcg recombinant hepatitis B vaccine followed by the same 20 mcg doses at 1, 4 and 8 weeks after first vaccine dose (Accelerated Vaccination protocol)</interventions>
    <comparator>Active treatment (intramuscular administration of 20 mcg recombinant hepatitis B vaccine followed by the same 20 mcg doses at 1 and 6 months after first dose) (Classic Vaccination protocol)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>antibody against hepatitis B surface-antigen (anti-HBS antibody) with a titer of 10 IU/L or more after blood analysis for each individual using laboratory kits</outcome>
      <timepoint>One month after administration of the first vaccine dose (before administering the second dose in the classic vaccination group and third dose in the accelerated vaccination group)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>anti HBS antibody with a titer of 10 IU/L or more after blood analysis for each individual using laboratory kits</outcome>
      <timepoint>8 months after administering the first vaccine dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male prisoners in Shiraz correctional and jail facilities</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>54</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.prior history of viral hepatitis B 2.prior history of hepatitis B vaccination 3.those tested positive for HBS antigen or anti-hepatitis B core (HBC) antibody at baseline 4.those with anti HBS antibody of 10 IU/L or more at baseline</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Fars</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Kamran B Lankarani</primarysponsorname>
    <primarysponsoraddress>Health Policy Research Center, 5th floor, Shiraz Medical School, Zand Ave, Shiraz, Fars province
P.C: 71345-1877</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shiraz University of Medical Sciences, Deputy of Research and Technology</fundingname>
      <fundingaddress>7th floor, Deputy of Research and Technology, Shiraz University of Medical Sciences, Zand Ave, Shiraz, Fars province.
P.C: 71345-1845</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>prisoners are among high risk groups for hepatitis B infection considering their high risk behaviors including injecting drug use or sexual behaviors. however classic 6 months vaccination might not be able to provide immunity rapidly enough and accelerated vaccination regimens can be of value in this situation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kamran B Lankarani</name>
      <address>Health Policy Research Center, 5th floor, Shiraz Medical School, Zand Ave, Shiraz, Fars province
P.C:71345-1877</address>
      <phone>0098 711 230 9615</phone>
      <fax>0098 711 230 9615</fax>
      <email>lankaran@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohsen Moghadami</name>
      <address>Health Policy Research Center, 5th floor, Shiraz Medical School, Zand Ave, Shiraz, Fars province
P.C: 71345-1877</address>
      <phone>0098 711 230 9615</phone>
      <fax>0098 711 230 9615</fax>
      <email>mohsen168@gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>